Retrophin Inc (RTRX)

22.57
NASDAQ : Health Care
Prev Close 23.27
Day Low/High 22.54 / 23.74
52 Wk Low/High 11.60 / 24.57
Avg Volume 766.90K
Exchange NASDAQ
Shares Outstanding 36.73M
Market Cap 854.73M
EPS 3.50
P/E Ratio 9.20
Div & Yield N.A. (N.A)

Latest News

Retrophin Announces Positive Results for Kidney Disease Drug

Retrophin Announces Positive Results for Kidney Disease Drug

Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease.

Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial

Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial

Leerink raised its price target on Retrophin's (RTRX) stock Wednesday after the company's sparsentan drug that treats a rare kidney disease saw positive results in a phase II clinical trial.

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Retrophin (RTRX) Weak On High Volume Today

Retrophin (RTRX) Weak On High Volume Today

Trade-Ideas LLC identified Retrophin (RTRX) as a weak on high relative volume candidate

Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson's Disease And Movement Disorders

Retrophin Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson's Disease And Movement Disorders

RE-024 treatment associated with clinically meaningful improvements in two PKAN patients

First Week of August 19th Options Trading For Retrophin (RTRX)

First Week of August 19th Options Trading For Retrophin (RTRX)

Investors in Retrophin, Inc. saw new options begin trading this week, for the August 19th expiration.

Retrophin (RTRX) Is Today's Strong On High Volume Stock

Retrophin (RTRX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Retrophin (RTRX) as a strong on high relative volume candidate

Retrophin Acquires Liquid Formulation Of Ursodeoxycholic Acid

Retrophin Acquires Liquid Formulation Of Ursodeoxycholic Acid

U.S. filing for primary biliary cholangitis indication anticipated in 2017

Notable Monday Option Activity: RTRX, TPX, ENOC

Notable Monday Option Activity: RTRX, TPX, ENOC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Retrophin, Inc. , where a total of 1,726 contracts have traded so far, representing approximately 172,600 underlying shares.

Commit To Purchase Retrophin At $10, Earn 14% Using Options

Commit To Purchase Retrophin At $10, Earn 14% Using Options

Investors considering a purchase of Retrophin, Inc. stock, but cautious about paying the going market price of $17.69/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Today's Weak On High Volume Stock: Retrophin (RTRX)

Today's Weak On High Volume Stock: Retrophin (RTRX)

Trade-Ideas LLC identified Retrophin (RTRX) as a weak on high relative volume candidate

Notable Wednesday Option Activity: RTRX, CONN, RMTI

Notable Wednesday Option Activity: RTRX, CONN, RMTI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Retrophin, Inc. , where a total of 2,626 contracts have traded so far, representing approximately 262,600 underlying shares.

Retrophin (RTRX) Flagged As Strong On High Volume

Retrophin (RTRX) Flagged As Strong On High Volume

Trade-Ideas LLC identified Retrophin (RTRX) as a strong on high relative volume candidate

Retrophin Completes Enrollment Of Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis

Retrophin Completes Enrollment Of Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis

Top-line results expected in the third quarter of 2016

First Week Of RTRX May 20th Options Trading

First Week Of RTRX May 20th Options Trading

Investors in Retrophin, Inc. saw new options become available this week, for the May 20th expiration.

Retrophin Announces New Data Supporting Further Clinical Development Of RE-024 For PKAN At The 2016 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting

Retrophin Announces New Data Supporting Further Clinical Development Of RE-024 For PKAN At The 2016 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting

Data From Four Posters Include Results of Phase 1 Study, Patient Case Report, and Preclinical Research